Menu
Search
|

Menu

Close
X

Gilead Sciences Inc GILD.OQ (NASDAQ Stock Exchange Global Select Market)

63.79 USD
+0.02 (+0.03%)
As of 4:00 PM EDT
chart
Previous Close 63.77
Open 63.80
Volume 2,733,059
3m Avg Volume 2,732,064
Today’s High 63.90
Today’s Low 62.93
52 Week High 79.61
52 Week Low 60.32
Shares Outstanding (mil) 1,275.51
Market Capitalization (mil) 81,339.30
Forward P/E 15.31
Dividend (Yield %) 0.63 ( 3.95 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.24 Mean rating from 29 analysts

KEY STATS

Revenue (mm, USD)
FY18
22,127
FY17
26,107
FY16
30,390
EPS (USD)
FY18
4.164
FY17
7.686
FY16
9.939
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.31
58.10
Price to Sales (TTM)
vs sector
3.68
8.84
Price to Book (MRQ)
vs sector
3.82
4.60
Price to Cash Flow (TTM)
vs sector
11.80
40.07
Total Debt to Equity (MRQ)
vs sector
127.75
17.66
LT Debt to Equity (MRQ)
vs sector
114.90
13.97
Return on Investment (TTM)
vs sector
9.80
12.12
Return on Equity (TTM)
vs sector
26.10
13.24

EXECUTIVE LEADERSHIP

Daniel O'Day
Chairman of the Board, Chief Executive Officer, Since 2019
Salary: --
Bonus: --
Robin Washington
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $953,231.00
Bonus: --
Kevin Young
Chief Operating Officer, Since 2016
Salary: $1,115,770.00
Bonus: --
John McHutchison
Executive Vice President - Clinical Research, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Gregg Alton
Executive Vice President - Corporate and Medical Affairs, Chief Patient Officer, Since 2018
Salary: $925,385.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

333 LAKESIDE DR
FOSTER CITY   CA   94404

Phone: +1650.5743000

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

SPONSORED STORIES